Filing Flows › ADC Therapeutics SA (ADCT) › Q2 2025
ADC Therapeutics SA (ADCT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
ADC Therapeutics SA (ADCT) reported revenue of $18.8M for the second quarter 2025 (Q2 2025), +8% from a year earlier and -18% from the quarter before. Operating margin was -234.3%, net loss $56.6M (300.7% of revenue).
ADC Therapeutics SA, Q2 2025: revenue $18.8M (+8% year over year), operating margin -234.3%, net loss $56.6M, operating cash flow −$24.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.8M | -18% | +8% |
| Operating profit | −$44.1M | — | — |
| Net earnings | −$56.6M | — | — |
| Operating cash flow | −$24.1M | — | — |
What changed
Revenue was $18.8M in Q2 2025, up 8% year over year and down 18% from the previous quarter. Product revenues, net was the largest line at 96% of revenue. Product revenues, net added $1.1M year over year (up 6%), 74% of the total change.
Operating costs exceeded revenue by $44.1M, an operating margin of -234.3%. Total costs grew 36% against revenue growth of 8%. The fastest-growing cost line was Other operating costs (+1044%). The quarter ended with a net loss of $56.6M, wider than the previous quarter's $38.6M loss.
Operating cash flow was −$24.1M. Non-cash charges added back $362K of depreciation and $1.8M of share-based compensation. Working capital and other items added $30.4M.
Questions
What was ADC Therapeutics SA's revenue in the second quarter 2025?
ADC Therapeutics SA (ADCT) reported revenue of $18.8M for the second quarter 2025 (Q2 2025), +8% from a year earlier and -18% from the quarter before.
Was ADC Therapeutics SA profitable in the second quarter 2025?
Operating loss was $44.1M (-234.3% of revenue) and net loss $56.6M.